---
title: "TransThera Sciences (Nanjing), Inc. (02617.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02617.HK.md"
symbol: "02617.HK"
name: "TransThera Sciences (Nanjing), Inc."
industry: "Biotechnology"
---

# TransThera Sciences (Nanjing), Inc. (02617.HK)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | HK Market |
| Website | [www.transthera.com](https://www.transthera.com) |

## Company Profile

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the tr...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -104.05 | 65/70 | - | - | - |
| PB | 42.37 | 58/70 | 116.75 | 70.19 | 30.55 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/02617.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02617.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02617.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
